Signature expression tracks with longer DOR in BOSTON XVd. (A) Kaplan-Meier curve of higher versus lower signature expression as a function of DOR in patients who achieved a partial response or better in (A) the BOSTON XVd cohort shows a significant association, whereas there is no significant difference in (B) patients in the BOSTON Vd cohort of non-selinexor–based therapy. DOR, duration of response; Vd, bortezomib and dexamethasone; XVd, selinexor, bortezomib, and dexamethasone.